Solid-state chemical stability of proteins and peptides

Journal of Pharmaceutical Sciences

Volumn 88, Issue 5, 1999, Pages 489-500

  Lai, M C ^a,b   Topp, E M ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXCIPIENT; PEPTIDE; PROTEIN;

DEAMINATION; DIMERIZATION; DRUG OXIDATION; DRUG STABILITY; MOISTURE; PH; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; SHORT SURVEY; SOLID STATE; TEMPERATURE DEPENDENCE;

EID: 0032945323     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980374e     Document Type: Short Survey

References (81)

1. Manning, M. C.; Patel, K.; Borchardt, R. T. Stability of protein pharmaceuticals. Pharm. Res. 1989, 6, 903-918.
2. Hageman, M. J. Water sorption and solid-state stability of proteins. In Stability of Protein Pharmaceuticals, Part A: Chemical and Physical Pathways of Protein Degradation; Ahern, T. J., Manning, M. C., Eds.; Plenum Press: New York, 1992; pp 273-309.
3. Carpenter, J. F.; Pikal, M. J.; Chang, B. S.; Randolph, T. W. Rational design of stable lyophilized protein formulations: Some practical advice. Pharm. Res. 1997, 14, 969-975.
4. Pikal, M. J.; Dellerman, K. M.; Roy, M. L.; Riggin, R. M. The effects of formulation variables on the stability of freeze-dried human growth hormone. Pharm. Res. 1991, 8, 427-436.
5. Pearlman, R.; Nguyen, T. J. Pharmaceutics of protein drugs. Pharm. Pharmacol. 1992, 44, 178-185.
6. Strickley, R. G.; Visor, G. C.; Lin, L.; Gu, L. Unexpected pH effect on the stability of moexipril lyophilized powder. Pharm. Res. 1989, 6, 971-975.
7. Bhatt, N.; Patel, K.; Borchardt, R. T. Chemical pathways of peptide degradation. I. Deamidation of adrenocorticotropic hormone. Pharm. Res. 1990, 7, 593-598.
8. Creighton, T. E. Proteins: Structures and Molecular Properties, 2nd ed.; W. H. Freeman and Company: New York, 1993; pp 464-469.
9. Costantino, H. R.; Langer, R.; Klibanov, A. M. Solid-phase aggregation of proteins under pharmaceutically relevant conditions. J. Pharm. Sci. 1994, 83, 1662-1669.
10. Becker, G. W.; Tackitt, P. M.; Bromer, W. W.; Lefeber, D. S.; Riggin, R. M. Isolation and characterization of a sulfoxide and a desamido derivative of biosynthetic human growth hormone, Biotechnol. Appl. Biochem. 1988, 10, 326-337.
11. Chang, B. S.; Reeder, G.; Carpenter, J. F. Development of a stable freeze-dried formulation of recombinant human interleukin-1 receptor agonist. Pharm. Res. 1996, 13, 243-249.
12. Hageman, M. J.; Bauer, J. M.; Possert, P. L.; Darrington, R. T. Preformulation studies oriented toward sustained delivery of recombinant somatotropins. J. Argicul. Food Chem. 1992, 40, 348-355.
13. Strickley, R. G.; Anderson, B. D. Solid-state stability of human insulin. I. Mechanism and the effect of water on the kinetics of degradation in lyophiles from pH 2-5 solutions. Pharm. Res. 1996, 13, 1142-1153.
14. Pikal, M. J.; Rigsbee, D. R. The stability of insulin in crystalline and amorphous solids: observation of greater stability for the amorphous form. Pharm. Res. 1997, 14, 1379-1387.
15. Patel, K.; Borchardt, R. T. Chemical pathways of peptide degradation. II. Kinetics of deamidation of an asparaginyl residue in a model hexapeptide. Pharm. Res. 1990, 7, 703-711.
16. Geiger, T.; Clarke, S. Deamidation, isomerization and racemization at asparaginyl and aspartyl residues in peptides. J. Biol. Chem. 1987, 262, 785-794.
17. Patel, K.; Borchardt, R. T. Chemical pathways of peptide degradation. III. Effect of primary sequence on the pathways of deamidation of asparaginyl residues in hexapeptides. Pharm. Res. 1990, 7, 787-793.
18. Oliyai, C.; Patel, J.; Carr, L.; Borchardt, R. T. Solid-state stability of lyophilized formulations of an asparaginyl residue in a model hexapeptide. J. Parenteral Sci. Technol. 1994, 48, 67-173.
19. Heckman, C.; DeMond, W.; Dixit, T.; Mauch, S.; Nuechterlein, M.; Stepaneko, A.; Williams, J. D.; Ye, M. Isolation and identification of peptide degradation products of heat stressed pramlintide injection drug product. Pharm. Res. 1998, 15, 650-659.
20. Lai, M. C.; Schowen, R. L.; Borchardt, R. T.; Topp, E. M. Chemical stability of peptides in polymers. I. Deamidation of a model hexapeptide in poly(vinyl alcohol) hydrogels and xerogels. J. Peptide Res. 1999, submitted.
21. Lai, M. C.; Hageman, M. J.; Schowen, R. L.; Borchardt, R. T.; Laird, B. B.; Topp, E. M. Chemical Stability of Peptides in Polymers. 2. Discriminating between Solvent and Plasticizing Effects of Water on Peptide Deamidation in Poly(vinyl pyrrolidone). J. Pharm. Sci. 1998, submitted.
22. Lai, M. C.; Hageman, M. J.; Schowen, R. L.; Borchardt, R. T.; Topp, E. M. Chemical Stability of Peptides in Polymers. 1. Effect of Water on Peptide Deamidation in Poly(vinyl alcohol) and Poly(vinyl pyrrolidone) Matrixes. J. Pharm. Sci. 1998, submitted.
23. Oliyai, C.; Patel, J. P.; Carr, L.; Borchardt, R. T. Chemical pathways of peptide degradation. VII. Solid-state chemical instability of an aspartyl residue in a model hexapeptide. Pharm. Res. 1994, 11, 901-908.
24. Oliyai, C.; Borchardt, R. T. Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide. Pharm. Res. 1993, 10, 95-102.
25. Li, S.; Patapoff, T. W.; Overcashier, D.; Hsu, C.; Nguyen, T. H.; Borchardt, R. T. Effects of Reducing Sugars on the Chemical Stability of Human Relaxin in the Lyophilized State. J. Pharm. Sci. 1996, 85, 873-877.
26. Leung, S. S.; Grant, D. J. W. Solid-State Stability Studies of Model Dipeptides: Aspartame and Aspartylphenylalanine. J. Pharm. Sci. 1997, 86, 64-71.
27. Bell, L. N.; Labuza, T. P. Aspartame degradation as a function of "water activity". In Water Relationships in Foods: Advances in the 1980s and Trends for the 1990s; Levine, H., Slade, L., Eds.; Advances in Experimental Medicine and Biology; Plenum: New York, 1991; Vol. 302, pp 337-350.
28. Kertscher, U.; Bienert, M.; Krause, E.; Sepetov, N.F.; Mehlis, B. Spontaneous chemical degradation of Substance P in the solid phase and in solution. Int. J. Pept. Protein Res. 1993, 41, 207-211.
29. Pikal, M. J.; Dellerman, K.; Roy, M. L. Formulation and stability of freeze-dried proteins: Effects of moisture and oxygen on the stability of freeze-dried formulations of human growth hormone. Dev. Biol. Stand. 1991, 74, 21-38.
30. Fransson, J.; Florin-Robertsson, E.; Axelsson, K.; Nyhlen, C. Oxidation of human insulin-like growth factor I in formulation studies: Kinetics of methionine oxidation in aqueous solution and in solid state. Pharm. Res. 1996, 13, 1252-1257.
31. Dubost, D. C.; Kaufman, M. J.; Zimmerman, J. A.; Bogusky, M. J.; Coddington, A. B.; Pitzenberger, S. M. Characterization of a solid-state reaction product from a lyophilized formulation of a cyclic heptapeptide. A novel example of an excipient-induced oxidation. Pharm. Res. 1996, 13, 1811-1814.
32. Hageman, M. J. The role of moisture in protein stability. Drug Dev. Ind. Pharm. 1988, 14, 2047-2070.
33. Labuza, T. P.; Saltmarch, M. The nonenzymatic browning reaction as affected by water in foods. In Water Activity: Influences on Food Quality; Rockland, L. B., Stewart, G. F., Eds; Academic Press: New York, 1981; pp 605-650.
34. Eichner, K.; Ciner-Doruk, M. Formation and decomposition of browning intermediates and visible sugar-amine browning reactions. In Water Activity: Influences on Food Quality; Rockland, L. B., Stewart, G. F., Eds; Academic Press: New York, 1981; pp 567-603.
35. Goldblith, S. A.; Tannenbaum, S. R. The nutritional aspects of the freeze-drying of foods. In Procedings of the 7th International Congress on Nutrition Pergamon Press: Oxford, 1966; Vol. 4, pp 432-445.
36. Costantino, H. R.; Langer, R.; Klibanov, A. M. Moisture-induced aggregation of lyophilized insulin. Pharm. Res. 1994, 11, 21-29.
37. Liu, W. R.; Langer, R.; Klibanov, A. M. Moisture-induced aggregation of lyophilized proteins in the solid state. Biotechnol. Bioeng. 1991, 37, 177-184.
38. Jordan, G. M.; Yoshioka, S.; Terao, T. The aggregation of bovine serum albumin in solution and in the solid state. J. Pharm. Pharmacol. 1994, 46, 182-185.
39. Chen, B. L.; Arakawa, T.; Morris, C. F.; Kenney, W. C.; Wells, C. M.; Pitt, C. G. Aggregation pathway of recombinant human keratinocyte growth factor and its stabilization. Pharm. Res. 1994, 11, 1581-1587.
40. Costantino, H. R.; Langer, R.; Klibanov, A. M. Aggregation of a lyophilized pharmaceutical protein, recombinant human albumin: Effect of moisture and stabilization by excipients. Biotechnology 1995, 13, 493-496.
41. Hora, M. S.; Rana, R. K.; Smith, F. W. Lyophilized formulations of recombinant tumor necrosis factor. Pharm. Res. 1992, 9, 33-36.
42. Townsend, M. W.; DeLuca, P. P. Use of lyoprotectants in the freeze-drying of a model protein, ribonuclease A. J. Parent. Sci. Technol. 1988, 42, 190-199.
43. Townsend, M. W.; Byron, P. R.; DeLuca, P. P. Effects of formulation additives on the degradation of freeze-dried ribonuclease A. Pharm. Res. 1990, 7, 1086-1091.
44. Townsend, M. W.; DeLuca, P. P. Nature of aggregates formed during storage of freeze-dried ribonuclease A. J. Pharm. Sci. 1961, 80, 63-66.
45. Schwendeman, S. P.; Costantino, H. R.; Gupta, R. K.; Siber, G. R.; Klibanov, A. M.; Langer, R. Stabilization of tetanus and diptheria toxoids against moisture-induced aggregation. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 11234-11238.
46. Connors, K. A.; Amidon, G. L.; Stella, V. J. Chemical Stability of Pharmaceuticals, 2nd ed.; John Wiley & Sons: New York, 1986; pp 115-134.
47. Ahlneck, C.; Zografi, G. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. Int. J. Pharm. 1990, 62, 87-95.
48. Carstensen, J. T. Effect of moisture on the stability of solid dosage forms. Drug. Dev. Ind. Pharm. 1988, 14, 1927-1969.
49. Karel, M.; Yong, S. Autoxidation-initiated reactions in foods. In Water Activity: Influences on Food Quality; Rockland, L. B., Stewart, G. F., Eds.; Academic Press: New York, 1981; pp 511-530.
50. Lea, C. H.; Hannan, R. S. Studies of the reaction between proteins and reducing sugars in the "dry" state. Biochim. Biophys. Acta 1949, 3, 313-325.
51. Lea, C. H.; Hannan, R. S.; Greaves, R. I. N. The reaction between proteins and reducing sugars in the "dry" state: Dried human blood plasma. Biochim. Biophys. Acta 1950, 4, 626-629.
52. Schwartz, H. M.; Lea, C. H. The reaction between proteins and reducing sugars in the "dry" state: Relative reactivity of the alpha- and epsilon-amino groups of insulin, Biochem. J. 1952, 50, 713-716.
53. Duckworth, R. B.; Allison, J. Y.; Clapperton, H. A. A. The aqueous environment for chemical change in intermediate moisture food. In Intermediate Moisture Foods; Davies, R., Birch, G. G., Parker, K. J., Eds.; Elsevier Applied: London, 1975; pp 89-99.
54. Shalaev, E. Y.; Zografi, G. How Does Residual Water Affect the Solid-State Degradation of Drugs in the Amorphous State? J. Pharm. Sci. 1996, 85, 1137-1141.
55. Wang, Y. J.; Hanson, M.A Parenteral formulations of proteins and peptides: Stability and stabilizers. J. Parenter. Sci. Technol. 1988, 10, 3-26.
56. Strickley, R. G.; Anderson, B. D. Solid-State Stability of Human Insulin. 2. Effect of Water on Reactive Intermediate Partitioning in Lyophiles from pH 2-5 Solutions: Stabilization against Covalent Dimer Formation. J. Pharm. Sci. 1997, 86, 645-653.
57. Streefland, L.; Auffret, A. D.; Franks, F. Bond cleavage reactions in solid aqueous carbohydrate solutions. Pharm. Res. 1998, 15, 843-849.
58. Johnson, R. E.; Lanaski, L. A.; Gupta, V.; Griffin, M.J.; Needham, T. E.; Zia, H. Stability of atriopeptin III in poly-(D,L-lactide-co-glycolide) microspheres. J. Controlled Release 1991, 17, 61-68.
59. Park, T. G.; Lu, W.; Crotts, G. Importance of in vitro experimental conditions on protein release kinetics, stability and polymer degradation. J. Controlled Release 1995, 33, 211-222.
60. Cleland, J. L.; Mac, A.; Boyd, B.; Yang, J.; Duenas, E. T.; Yueng, D.; Brooks, D.; Hsu, C.; Chu, H.; Mukku, V.; Jones, A. J. S. The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res. 1997, 14, 420-425.
61. Johnson, O. L.; Jaworowicz, W.; Cleland, J. L.; Bailey, L.; Charnis, M.; Duenas, E.; Wu, C.; Shepard, D.; Magil, S.; Last, T.; Jones, A. J. S.; Putney, S. D. The stabilization and encapsulation of human growth hormone into biodegradable microspheres. Pharm. Res. 1997, 14, 730-735.
62. Putney, S. D.; Burke, P. A. Improving protein therapeutics with sustained-release formulations. Nature Biotechnol. 1998, 16, 153-157.
63. Berglund, P. The effect of temperature on peptide deamidation in polymer matrixes. Master's Thesis, Danish Royal School of Pharmacy, Copenhagen, 1998.
64. Yoshioka, S.; Aso, Y.; Kojima, S. Dependence of the molecular mobility and protein stability of freeze-dried gamma-globulin formulations on the molecular weight of dextran. Pharm. Res. 1997, 14, 736-741.
65. Ron, E.; Turek, T.; Mathiowitiz, E.; Chasin, M.; Hageman, M.; Langer, R. Controlled release of polypeptides from polyanhydrides. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 4176-4180.
66. Townsend, M. W.; DeLuca, P. P. Stability of ribonuclease A in solution and the freeze-dried state. J. Pharm. Sci. 1900, 79, 1083-1086.
67. Pikal, M. J. Excipients for lyophile formulations. 1998 Walter F. Enz Lecture, presented at The University of Kansas, Department of Pharmaceutical Chemistry, July 30, 1998.
68. Song, Y.; Borchardt, R. T.; Schowen, R. L.; Topp, E. M. Effect of pH on peptide deamidation in polymeric matrixes, presented at the American Association of Pharmaceutical Scientists Midwest Regional Meeting, Chicago, IL, May 17, 1999.
69. Davio, S. R.; Hageman, M. J. Characterization and formulation considerations for recombinantly derived bovine somatotropin. In Stability and Characterization of Protein and Peptide Drugs: Case Histories; Wang, Y. J., Pearlman, R., Eds.; Plenum Press: New York, 1993; pp 59-89.
70. Carstensen, J. T.; Morris, T. Chemical stability of indomethacin in the solid amorphous and molten states, J. Pharm. Sci. 1993, 82, 657-659.
71. Sperling, L. H. Introduction to Physical Polymer Science; John Wiley & Sons: New York, 1986.
72. Levine, H.; Slade, L. The glassy state phenomenon in food molecules. In The Glassy State in Foods; Blanshard, J. M. V., Lillford, P. J., Eds.; Nottingham Press: Nottingham, 1993; pp 35-101.
73. Chang, B. S.; Beauvais, R. M.; Dong, A.; Carpenter, J. F. Physical factors affecting the storage stability of freeze-dried interleukin-1 receptor antagonist: Glass transition and protein conformation. Arch. Biochim. Biophys. 1996, 331, 249-258.
74. Hancock, B. C.; Zografi, G. Molecular mobility of amorphous pharmaceutical solids below their glass transition. Pharm. Res. 1995, 12, 799-806.
75. Oksanen, C. A.; Zografi, G. Molecular mobility in mixtures of absorbed water and solid poly(vinyl pyrrolidone). Pharm. Res. 1993, 10, 791-799.
76. Roy, M. L.; Pikal, M. J.; Rickard, E. C.; Maloney, A. M. The effects of formulation and moisture on the stability of a freeze-dried monoclonal antibody-vinca conjugate: A test of the WLF glass transition theory. Dev. Biol. Standard. 1992, 74, 323-340.
77. Bell, L. N.; Hageman, M. J. Differentiating between the effects of water activity and glass transition dependent mobility on a solid-state chemical reaction: Aspartame degradation. J. Agric. Food Chem. 1994, 42, 2398-2401.
78. Yoshioka, S.; Aso, Y.; Kojima, S. The effect of excipients on the molecular mobility of lyophilized formulations, as measured by glass transition temperature and NMR relaxation-based critical mobility temperature. Pharm. Res. 1999, 16, 135-140.
79. Yoshioka, S.; Aso, Y.; Nakai, Y.; Kojima, S. Effect of High Molecular Mobility of Poly(vinyl alcohol) on Protein Stability of Lyophilized γ-Globulin Formulations. J. Pharm. Sci. 1998, 87, 147-151.
80. Xie, M.; Schowen, R. L. Secondary Structure and Protein Deamidation. J. Pharm. Sci. 1999, 88, 8-13.
81. Yang, T. H.; Dong, A.; Meyer, J.; Johnson, O. L.; Cleland, J. L., Carpenter, J. F. Use of Infrared Spectroscopy to Assess Secondary Structure of Human Growth Hormone within Biodegradable Microspheres. J. Pharm. Sci. 1999, 88, 161-165.